Article

OGDHL regulates tumor growth, neuroendocrine marker expression, and nucleotide abundance in prostate cancer

2025-06-01

Abstract excerpt

As cancer cells evade therapeutic pressure and adopt alternate lineage identities not commonly observed in the tissue of origin, they likely adopt alternate metabolic programs to support their evolving demands. Targeting these alternative metabolic programs in distinct molecular subtypes of aggressive prostate cancer may lead to new therapeutic approaches to combat treatment-resistance. We identify the poorly stud...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2c0dd4b4-90b7-5bbc-84af-bd30ab891f88
DOI: 10.1101/2025.05.28.656673

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

OGDHL regulates tumor growth, neuroendocrine marker expression, and nucleotide abundance in prostate cancerDOI 10.1101/2025.05.28.656673Read

Multi-Omics Profiling Exposes a Metabolic Void in Prostate Cancer Models That Drives Precursor Dependence and Clinical ProgressionSemantic proximity Read

LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate CancerSemantic proximity Read

Reprogramming of Isocitrate Dehydrogenases Expression and Activity by the Androgen Receptor in Prostate CancerSemantic proximity Read

Integrated metabolic and transcriptomic landscapes reveal an obligate reliance on exogenous steroid conversion for prostate cancer survivalSemantic proximity Read

DPYSL3B is a regulator of chemoresistance via DNA repair and metabolic reprogramming in prostate cancerSemantic proximity Read

MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancerSemantic proximity Read

Androgen receptor inhibition induces metabolic reprogramming and increased reliance on oxidative mitochondrial metabolism in prostate cancerSemantic proximity Read

OXPHOS remodeling in high-grade prostate cancer involves mtDNA mutations and increased succinate oxidation.Semantic proximity Read

Single-cell analysis revealing the metabolic landscape of prostate cancerSemantic proximity Read

PGC-1α drives small cell neuroendocrine cancer progression towards an ASCL1-expressing subtype with increased mitochondrial capacitySemantic proximity Read

Personalized Medicine for Prostate Cancer: Is Targeting Metabolism a Reality?Semantic proximity Read

Transcending frontiers in prostate cancer: the role of oncometabolites on epigenetic regulation, CSCs, and tumor microenvironment to identify new therapeutic strategies.Semantic proximity Read